Trial Profile
Cognitive Effects of Nimodipine in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Nimodipine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 22 Jun 2023 Status changed from suspended to completed.
- 26 Oct 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 26 Oct 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.